Anjali Nemawarkar, MD
Internal Medicine · Austin, TXNPI 1093779555
Payments from drug & device makers
Across 156 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$419
- Boehringer Ingelheim$321
- Novo Nordisk$307
- GSK$231
- Astellas Pharma US Inc$218
- AstraZeneca$144
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,956100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $419 |
| Boehringer Ingelheim | 17 | $321 |
| Novo Nordisk | 16 | $307 |
| GSK | 12 | $231 |
| Astellas Pharma US Inc | 11 | $218 |
| AstraZeneca(2 entities) | 8 | $144 |
| Pfizer | 5 | $119 |
| Phathom Pharmaceuticals, Inc. | 1 | $97 |
| Exact Sciences | 4 | $88 |
| Biogen | 3 | $82 |
| Mylan Specialty L.p. | 3 | $81 |
| Dynavax Technologies Corporation | 6 | $81 |
| Novartis | 5 | $75 |
| Abbott | 3 | $60 |
| Inspire Medical Systems, Inc. | 2 | $57 |
| Verona Pharma, Inc. | 2 | $54 |
| Bayer | 3 | $50 |
| Amgen | 3 | $47 |
| Dexcom, Inc. | 2 | $38 |
| Boston Scientific | 1 | $32 |
| AbbVie | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Argenx US, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Pulmonx Corporation | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Intuity Medical Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$2,956 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $115,066 |
| JardianceEmpagliflozin | 54 | $63,758 |
| EliquisApixaban | 59 | $59,030 |
| FarxigaDapagliflozin Propanediol | 51 | $54,602 |
| TrulicityDulaglutide | 35 | $46,937 |
| JanuviaSitagliptin Phosphate | 38 | $42,714 |
| MyrbetriqMirabegron | 44 | $36,876 |
| MounjaroTirzepatide | 32 | $33,734 |
| TradjentaLinagliptin | 30 | $31,554 |
| XareltoRivaroxaban | 16 | $24,691 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,396 |
| WegovySemaglutide | 11 | $13,849 |
| Mirabegron ErMirabegron | 15 | $9,084 |
| Levothyroxine Sodium | 586 | $8,266 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $307 | $128,915134 claims |
| Boehringer IngelheimJardiance, Tradjenta | $321 | $95,31284 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $419 | $80,67167 claims |
| AstraZenecaFarxiga, Symbicort | $144 | $59,92863 claims |
| PfizerEliquis | $119 | $59,03059 claims |
| MerckJanuvia | $11 | $42,71438 claims |
| Astellas Pharma US IncMyrbetriq | $218 | $36,87644 claims |
| GSKTrelegy Ellipta | $231 | $15,39624 claims |
| AbbVieSynthroid | $30 | $4,62285 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Austin
- Theresa PhamAustin$6.3M
- Lu Ann BundrantAustin$5.4M
- Antonia DavidsonAustin$4.2M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.